Nothing Special   »   [go: up one dir, main page]

CY1115349T1 - Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου - Google Patents

Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου

Info

Publication number
CY1115349T1
CY1115349T1 CY20141100422T CY141100422T CY1115349T1 CY 1115349 T1 CY1115349 T1 CY 1115349T1 CY 20141100422 T CY20141100422 T CY 20141100422T CY 141100422 T CY141100422 T CY 141100422T CY 1115349 T1 CY1115349 T1 CY 1115349T1
Authority
CY
Cyprus
Prior art keywords
cxcr4
antibodies
cleaned
cancer treatment
relates
Prior art date
Application number
CY20141100422T
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Alexandra Jouhanneaud
Véronique Grenier-Caussanel
Sven Berger
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42556901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115349(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/749,891 external-priority patent/US8557964B2/en
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of CY1115349T1 publication Critical patent/CY1115349T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ένα νέο απομονωθέν εξανθρωπισμένο αντίσωμα ή τις λαμβανόμενες ενώσεις ή λειτουργικά θραύσματα του ιδίου, ικανά σύνδεσης προς CXCR4, αλλά επίσης διέγερσης διαμορφωτικών μεταβολών CXCR4 ομοδιμερών ή/και ετεροδιμερών. Ειδικότερα, η παρούσα εφεύρεση αφορά σε hz515H7 αντισώματα, ειδικά για την CXCR4 πρωτεΐνη, καθώς επίσης χρήση αυτών για τη θεραπεία καρκίνου. Επίσης καλύπτονται φαρμακευτικές συνθέσεις που αποτελούνται από τέτοια αντισώματα και μέθοδος για την επιλογή τέτοιων αντισωμάτων.
CY20141100422T 2010-03-30 2014-06-11 Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου CY1115349T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/749,891 US8557964B2 (en) 2008-10-01 2010-03-30 Anti CXCR4 antibodies and their use for the treatment of cancer
EP10290167A EP2371863A1 (en) 2010-03-30 2010-03-30 Humanized anti CXCR4 antibodies for the treatment of cancer
EP11711554.3A EP2552963B1 (en) 2010-03-30 2011-03-30 Humanized anti cxcr4 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1115349T1 true CY1115349T1 (el) 2017-01-04

Family

ID=42556901

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100422T CY1115349T1 (el) 2010-03-30 2014-06-11 Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου

Country Status (30)

Country Link
US (1) US9249223B2 (el)
EP (2) EP2371863A1 (el)
JP (1) JP5749330B2 (el)
KR (1) KR101838310B1 (el)
CN (1) CN102939306B (el)
AR (1) AR080740A1 (el)
AU (1) AU2011234458B2 (el)
CA (1) CA2794407C (el)
CL (1) CL2012002700A1 (el)
CO (1) CO6571881A2 (el)
CY (1) CY1115349T1 (el)
DK (1) DK2552963T3 (el)
ES (1) ES2469369T3 (el)
HK (1) HK1178910A1 (el)
HR (1) HRP20140502T1 (el)
IL (1) IL222198A (el)
MA (1) MA34175B1 (el)
MX (1) MX2012011206A (el)
NZ (1) NZ603182A (el)
PL (1) PL2552963T3 (el)
PT (1) PT2552963E (el)
RS (1) RS53405B (el)
RU (1) RU2595394C2 (el)
SG (1) SG184308A1 (el)
SI (1) SI2552963T1 (el)
TN (1) TN2012000466A1 (el)
TW (1) TWI549689B (el)
UA (1) UA106529C2 (el)
WO (1) WO2011121040A1 (el)
ZA (1) ZA201208015B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Ｈｉｖの治療用抗体
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
TWI671317B (zh) * 2013-08-02 2019-09-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體-藥物結合物
EP4257599A3 (en) * 2016-01-13 2024-01-17 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
EP3774840A1 (en) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
EP4005923B1 (de) 2020-11-30 2023-08-30 Bucher Leichtbau AG Bordverpflegungsstation
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
AU2004259406A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
KR20170123712A (ko) * 2006-10-02 2017-11-08 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
UY30838A1 (es) * 2006-12-26 2008-07-31 Centro Inmunologia Molecular Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
CN102027015A (zh) * 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
EP2285833B1 (en) * 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
TWI549689B (zh) 2016-09-21
CL2012002700A1 (es) 2013-04-26
SI2552963T1 (sl) 2014-07-31
MA34175B1 (fr) 2013-04-03
SG184308A1 (en) 2012-11-29
CN102939306B (zh) 2015-07-22
ES2469369T3 (es) 2014-06-18
US20130031647A1 (en) 2013-01-31
AR080740A1 (es) 2012-05-02
IL222198A (en) 2016-09-29
TN2012000466A1 (en) 2014-01-30
RS53405B (en) 2014-10-31
IL222198A0 (en) 2012-12-31
KR20130012132A (ko) 2013-02-01
CN102939306A (zh) 2013-02-20
WO2011121040A1 (en) 2011-10-06
AU2011234458B2 (en) 2015-02-12
CA2794407A1 (en) 2011-10-06
RU2595394C2 (ru) 2016-08-27
CO6571881A2 (es) 2012-11-30
DK2552963T3 (da) 2014-04-07
UA106529C2 (uk) 2014-09-10
JP2013523106A (ja) 2013-06-17
HK1178910A1 (en) 2013-09-19
US9249223B2 (en) 2016-02-02
EP2552963A1 (en) 2013-02-06
AU2011234458A1 (en) 2012-11-15
NZ603182A (en) 2013-12-20
TW201136608A (en) 2011-11-01
EP2552963B1 (en) 2014-03-26
KR101838310B1 (ko) 2018-03-13
PL2552963T3 (pl) 2014-08-29
EP2371863A1 (en) 2011-10-05
CA2794407C (en) 2019-02-19
HRP20140502T1 (hr) 2014-07-04
RU2012145232A (ru) 2014-05-10
MX2012011206A (es) 2013-02-11
JP5749330B2 (ja) 2015-07-15
PT2552963E (pt) 2014-06-03
ZA201208015B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1116886T1 (el) C-met αντισωματα
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
CY1118014T1 (el) Aνti-il-23 αντισωματα
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201492149A8 (ru) St2-антигенсвязывающие белки
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
IN2014CN03936A (el)
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201401204A1 (ru) Антитела к il-23p19
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CY1120803T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
CY1118254T1 (el) Αντισωματα toy βμρ-6
EA201390117A1 (ru) Композиция антител к vegfr-3